Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study
Satılmış Bilgin, Özge Kurtkulağı, Tuba Taslamacıoğlu Duman, Burçin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gülali Aktaş
Topics & Concepts
EmpagliflozinMedicineInternal medicineType 2 diabetesDiabetes mellitusBody mass indexType 2 Diabetes MellitusEndocrinologyBlood pressureTriglycerideCardiologyCholesterolDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer